Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Shionogi & CofiledCriticalAstrazeneca Ab
Priority claimed from PCT/GB2000/000278external-prioritypatent/WO2000045817A1/en
Application grantedgrantedCritical
Publication of DK1185274T3publicationCriticalpatent/DK1185274T3/en
PROCEDURE FOR PREPARING THE CALCIUM SALT OF ROSUVASTATIN (E) -7- [4- (4-FLUORPHENYL) -6-ISOPROPYL-2- [METHYL (METHYLSULPHONYL) AMINO] -PYRIMIDIN-5-YL] (3) 5-DIHYDROXYHEPT-6-ACID AND CRYSTALLINIC INTERMEDIATES THEREOF
Crystalline form of bis [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [Methyl (methylsulfonyl) amino] pyrimidin-5-yl] -3,5-yl -6-LIGHT ACID] CALCIUM SALT
Combinations of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]-amino]-benzonitrile and nucleoside or nucleotide reverse transcriptase inhibitors, compositions comprising them and uses thereof
A method of preparation of the hemi-calcium salt of (e)-7- [4-(4-fluorophenyl)-6-isopropyl-2- [me thyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxy-6-heptenoic acid
Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4